BENLYSTA
Biological
GlaxoSmithKline, LLC.
Total Payments
$43.1M
Transactions
125,268
Doctors
13,446
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.4M | 19,363 | 4,873 |
| 2023 | $4.7M | 23,145 | 6,277 |
| 2022 | $6.4M | 21,959 | 6,188 |
| 2021 | $4.5M | 19,594 | 5,231 |
| 2020 | $5.5M | 9,256 | 2,568 |
| 2019 | $8.4M | 12,418 | 2,859 |
| 2018 | $4.1M | 9,963 | 2,569 |
| 2017 | $6.0M | 9,570 | 2,735 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.8M | 4,300 | 73.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.6M | 3,027 | 15.4% |
| Food and Beverage | $2.4M | 114,926 | 5.6% |
| Consulting Fee | $1.5M | 1,148 | 3.5% |
| Travel and Lodging | $608,937 | 1,706 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $101,800 | 25 | 0.2% |
| Education | $2,908 | 135 | 0.0% |
| Grant | $1,039 | 1 | 0.0% |
Payments by Type
Research
$31.8M
4,300 transactions
General
$11.3M
120,968 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $3.9M | 23 |
| A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | GlaxoSmithKline, LLC. | $2.5M | 0 |
| A Phase 3 4, Multi Center, Randomized, Double Blind, Placebo Controlled, 52 Week Study to Evaluate the Efficacy and Safety of Belimumab HGS1006 in Adult Subjects of Black Race with Systemic Lupus Erythematosus SLE | GlaxoSmithKline, LLC. | $1.6M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000208855 | GlaxoSmithKline, LLC. | $1.6M | 0 |
| A PHASE 3/4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | GlaxoSmithKline, LLC. | $1.3M | 0 |
| WEUKBRE6076: BELIMUMAB (BENLYSTA) PREGNANCY REGISTRY PROTOCOL | GlaxoSmithKline, LLC. | $1.3M | 6 |
| A Randomized, Double Blind, Placebo Controlled 52 Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody Positive Systemic Lupus Erythematosus Receiving Belimumab | GlaxoSmithKline, LLC. | $1.3M | 0 |
| BELIMUMAB (BENLYSTA) PREGNANCY REGISTRY | GlaxoSmithKline, LLC. | $1.0M | 0 |
| A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis | GlaxoSmithKline, LLC. | $922,738 | 0 |
| Benlysta prospective observational registry | GlaxoSmithKline, LLC. | $874,788 | 0 |
| A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | GlaxoSmithKline, LLC. | $808,597 | 33 |
| 209482 | GlaxoSmithKline, LLC. | $781,036 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BELIMUMAB AND | GlaxoSmithKline, LLC. | $738,188 | 0 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALU | GlaxoSmithKline, LLC. | $682,896 | 0 |
| PILOT TRIAL OF BELIMUMAB IN EARLY LUPUS | GlaxoSmithKline, LLC. | $679,315 | 0 |
| BENLYSTA (BELIMUMAB) (I.V.) - SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | GlaxoSmithKline, LLC. | $596,184 | 0 |
| B CELL HETEROGENEITY AND RESPONSE TO BELIMUMAB IN SLE | GlaxoSmithKline, LLC. | $578,265 | 0 |
| 208855 | GlaxoSmithKline, LLC. | $556,910 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK STUDY TO ASSESS | GlaxoSmithKline, LLC. | $552,255 | 0 |
| WEUKBRE6076 Belimumab BENLYSTA Pregnancy Registry Protocol | GlaxoSmithKline, LLC. | $539,848 | 1 |
Top Doctors Receiving Payments for BENLYSTA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Jacksonville, FL | $31.8M | 4,073 |
| , MD | Rheumatology | Saint Louis, MO | $271,715 | 274 |
| , M.D | Rheumatology | Clinton, MD | $246,366 | 249 |
| , MD | Internal Medicine | Redwood City, CA | $209,905 | 219 |
| , M.D | Internal Medicine | Birmingham, AL | $197,541 | 240 |
| , M.D | Nephrology | Dallas, TX | $189,773 | 194 |
| , MD | Rheumatology | St Petersburg, FL | $187,179 | 196 |
| , M.D | Rheumatology | Sugar Land, TX | $171,121 | 164 |
| , MD | Specialist | Fort Lauderdale, FL | $164,912 | 162 |
| , DO | Rheumatology | Austin, TX | $162,141 | 161 |
| , M.D., PH.D | Internal Medicine | Chapel Hill, NC | $160,058 | 125 |
| , D.O | Rheumatology | Fullerton, CA | $148,425 | 155 |
| , M.D | Nephrology | New York, NY | $141,228 | 105 |
| , MD | Rheumatology | Franklin, WI | $137,897 | 187 |
| , MD | Rheumatology | Concord, NC | $134,278 | 126 |
| , M.D | Hospitalist | Aventura, FL | $131,524 | 136 |
| , MD | Rheumatology | Los Angeles, CA | $129,962 | 96 |
| , M.D | Rheumatology | San Leandro, CA | $123,458 | 143 |
| , MD | Internal Medicine | Indianapolis, IN | $119,503 | 110 |
| , MD | Rheumatology | Orange, CA | $108,166 | 86 |
| , M.D | Rheumatology | Wichita Falls, TX | $105,106 | 177 |
| , M.D | Rheumatology | Sun City, AZ | $104,914 | 154 |
| , MD | Rheumatology | Saint Clair Shores, MI | $101,877 | 184 |
| , D.O | Internal Medicine | Arlington, TX | $99,464 | 176 |
| , MD | Rheumatology | Bannockburn, IL | $97,523 | 143 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $43.1M
Product Information
- Type Biological
- Total Payments $43.1M
- Total Doctors 13,446
- Transactions 125,268
About BENLYSTA
BENLYSTA is a biological associated with $43.1M in payments to 13,446 healthcare providers, recorded across 125,268 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2024. In 2024, $3.4M was paid across 19,363 transactions to 4,873 doctors.
The most common payment nature for BENLYSTA is "Unspecified" ($31.8M, 73.8% of total).
BENLYSTA is associated with 20 research studies, including "A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED," ($3.9M).